Protection against chemotherapy induced mucositis by TGF‐β2 in childhood cancer patients: Results from a randomized cross‐over study

Mucositis is one of the most frequent and severe side‐effect of chemotherapy in childhood‐cancer patients for which there is no prophylaxis available. The efficacy and feasibility of a TGF‐β2‐enriched feeding for preventing oral and gastro‐intestinal‐mucositis in childhood‐cancer patients were studied.

[1]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[2]  Marilyn Hockenberry,et al.  Symptom Management Research in Children With Cancer , 2004, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[3]  L. Elting,et al.  Perspectives on cancer therapy‐induced mucosal injury , 2004, Cancer.

[4]  S. Sonis.  The pathobiology of mucositis , 2004, Nature Reviews Cancer.

[5]  Scott B Cantor,et al.  The burdens of cancer therapy , 2003, Cancer.

[6]  C. Serdar,et al.  Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Smeets,et al.  Transforming Growth Factor-β2 protects the small intestine during methotrexate treatment in rats possibly by reducing stem cell cycling , 2002, British Journal of Cancer.

[8]  D. McGuire.  Mucosal tissue injury in cancer therapy. More than muscositis and mouthwash. , 2002, Cancer practice.

[9]  D. Neuberg,et al.  A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation , 2002, Bone Marrow Transplantation.

[10]  C. Potten,et al.  Protection against mucosal injury by growth factors and cytokines. , 2001, Journal of the National Cancer Institute. Monographs.

[11]  S. Sonis,et al.  Topical Transforming Growth Factor-&bgr;3 in the Prevention or Alleviation of Chemotherapy-Induced Oral Mucositis in Patients with Lymphomas or Solid Tumors , 2001, Journal of immunotherapy.

[12]  K. Rex,et al.  The effects of repeated doses of keratinocyte growth factor on cell proliferation in the cellular hierarchy of the crypts of the murine small intestine. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[13]  F. Spijkervet,et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Cummins,et al.  Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans , 2000, Gut.

[15]  F. Spijkervet,et al.  Phase I study of transforming growth factor-beta3 mouthwashes for prevention of chemotherapy-induced mucositis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  M. Bonnaure-Mallet,et al.  Oral complications during treatment of malignant diseases in childhood: effects of tooth brushing. , 1998, European journal of cancer.

[17]  P. Calabresi,et al.  Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS , 1998, Neurology.

[18]  S. Sonis,et al.  The impact of mucositis on α‐hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies , 1998, Cancer.

[19]  D. Lacey,et al.  Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. , 1998, Cancer research.

[20]  D. Rifkin,et al.  Latent transforming growth factor-beta: structural features and mechanisms of activation. , 1997, Kidney international.

[21]  C. Ambrosino,et al.  Transforming growth factor-beta3 protection of epithelial cells from cycle-selective chemotherapy in vitro. , 1997, Biochemical pharmacology.

[22]  M. Rogers,et al.  Transforming growth factor beta in bovine milk: concentration, stability and molecular mass forms. , 1996, The Journal of endocrinology.

[23]  James M. Roberts,et al.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. , 1993, Science.

[24]  C. Potten,et al.  Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line , 1992, Cell proliferation.

[25]  C. Sarraf,et al.  The nature of cytotoxic drug-induced cell death in murine intestinal crypts. , 1992, British Journal of Cancer.

[26]  S. Sonis,et al.  Prevention and management of oral mucositis induced by antineoplastic therapy. , 1991, Oncology.

[27]  R. Knecht,et al.  Separation, purification, and sequence identification of TGF-β1 and TGF-β2 from bovine milk , 1991 .

[28]  Fayle Sa,et al.  Oral complications in pediatric oncology patients. , 1991 .

[29]  H. Moses,et al.  The cell biology of transforming growth factor β , 1990 .

[30]  C. Potten,et al.  Further studies on the response of intestinal crypt cells of different hierarchical status to eighteen different cytotoxic agents. , 1987, British Journal of Cancer.

[31]  C. Potten,et al.  Response of intestinal cells of differing topographical and hierarchical status to ten cytotoxic drugs and five sources of radiation. , 1983, British Journal of Cancer.

[32]  M. Palmer,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.

[33]  S. Sonis,et al.  Oral complications in patients receiving treatment for malignancies other than of the head and neck. , 1978, Journal of the American Dental Association.

[34]  T. Shea,et al.  Palifermin for oral mucositis after intensive therapy for hematologic cancers , 2017 .

[35]  F. Burlage,et al.  Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study , 2004, Supportive Care in Cancer.

[36]  J. Epstein,et al.  Patient reports of complications of bone marrow transplantation , 2000, Supportive Care in Cancer.

[37]  S. Sonis,et al.  Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. , 1998, Oral oncology.

[38]  J. Haley,et al.  Transforming growth factor-β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis , 1997 .

[39]  C. Potten,et al.  Pretreatment with transforming growth factor beta-3 protects small intestinal stem cells against radiation damage in vivo. , 1997, British Journal of Cancer.

[40]  A. Dasanayake,et al.  Oral complications in children with cancer. , 1993, Oral surgery, oral medicine, and oral pathology.

[41]  R. Knecht,et al.  Separation, purification, and sequence identification of TGF-beta 1 and TGF-beta 2 from bovine milk. , 1991, Journal of protein chemistry.

[42]  M. Curzon,et al.  Oral complications in pediatric oncology patients. , 1991, Pediatric dentistry.

[43]  J. Massagué,et al.  The transforming growth factor-beta family. , 1990, Annual review of cell biology.

[44]  H. Moses,et al.  The cell biology of transforming growth factor beta. , 1990, Biochimica et biophysica acta.

[45]  M. Sporn,et al.  Type beta transforming growth factor: a bifunctional regulator of cellular growth. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. B. Jackson,et al.  Perspectives on , 1981, J. Am. Soc. Inf. Sci..